Psyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026Psyence Group2026-01-23T08:22:41+02:00January 22, 2026|Read More
Psyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective DatePsyence Group2026-01-21T07:57:02+02:00January 20, 2026|Read More
Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock SplitPsyence Group2026-01-15T09:08:36+02:00January 15, 2026|Read More
Psyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value OpportunityPsyence Group2026-01-12T16:56:26+02:00January 12, 2026|Read More
Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and strengthens Balance Sheet with no debt and $12m cashPsyence Group2026-01-06T08:40:06+02:00January 6, 2026|Read More
Psyence BioMed Announces Approval for Use of PsyLabs’ Psilocybin Product in Phase IIb Clinical TrialPsyence Group2025-12-19T11:05:00+02:00December 19, 2025|Read More
Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity SciencePsyence Group2025-12-09T14:09:56+02:00December 9, 2025|Read More
Opinion: The Future of Human Longevity Will Be Transformational – And Nature May Hold the KeyPsyence Group2025-11-28T10:04:50+02:00November 28, 2025|Read More
